Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Bristol-Myers Squibb Company (BMY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.6%. By the end of trading, Bristol-Myers Squibb Company fell 35 cents (-1.1%) to $31.57 on average volume. Throughout the day, 13.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.8 million shares. The stock ranged in price between $31.47-$32.07 after having opened the day at $32 as compared to the previous trading day's close of $31.92. Other companies within the Health Care sector that declined today were: Pluristem Therapeutic (PSTI), down 12.6%, Aoxing Pharmaceutical Company (AXN), down 12.5%, Prima Biomed Ltd. ADR (PBMD), down 11.8%, and Bovie Medical Corporation (BVX), down 10.8%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $53.34 billion and is part of the drugs industry. The company has a P/E ratio of 15.3, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 10% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, two analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

• You can view the full Bristol-Myers Squibb Ratings Report.

On the positive front, IntelliPharmaCeutics International (IPCI), up 15.5%, Thermogenesis Corporation (KOOL), up 13.9%, Clovis Oncology (CLVS), up 11.9%, and Alliance HealthCare Services (AIQ), up 10.4%, were all gainers within the health care sector with Edwards Life (EW) being today's featured health care sector leader.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

 

For more information on Bristol-Myers Squibb Company click any of the following:

• Bristol-Myers Squibb Company Stock Price

• Bristol-Myers Squibb Company Analyst Ratings

• Bristol-Myers Squibb Company Key Stats & Profile

• Bristol-Myers Squibb Company Earnings

• Bristol-Myers Squibb Company Ratio Comparison

• Bristol-Myers Squibb Company Growth Rates

• Bristol-Myers Squibb Company Balance Sheet

• Bristol-Myers Squibb Company Cash Flow

• Bristol-Myers Squibb Company Income Statement